The Latest in Lung Cancer

Durvalumab combos beat monotherapy for unresectable stage 3 NSCLC

September 20, 2021

Lung Cancer

Mediastinal relapse risk lower with PORT, but no survival benefit

September 20, 2021

Lung Cancer

‘Urgent’ need to understand immunotherapy de-escalation in NSCLC

September 17, 2021

Lung Cancer

Tackling grief, loss in patients with advanced lung cancer

September 17, 2021

Lung Cancer

ESMO 2021: Impressive clinical research despite pandemic

September 16, 2021

Lung Cancer

POSEIDON: Two ICIs plus chemo up survival in mNSCLC

September 15, 2021

Lung Cancer

Combo treatment for NSCLC with brain metastases extends survival by two years for some

September 15, 2021

COVID is especially dangerous for mesothelioma

September 15, 2021

Lung Cancer

Pandemic strategies to boost trial enrollment should stay

September 13, 2021

Air pollution – second leading cause of lung cancer

September 13, 2021

Unequal resource distribution underlies lung cancer disparities

September 10, 2021

Finding the most bang for the buck with adjuvant atezolizumab for NSCLC

September 10, 2021

Lung Cancer

Microwave ablation an alternative therapy in lung malignancy

September 10, 2021

Lung Cancer

Metformin disappoints in two phase 2 lung cancer trials

September 3, 2021

Lung Cancer

A case is building for personalized, genome-based radiation dosing

September 1, 2021